• Reset
2.15.22 | Policy
SWHR Statement on Dr. Robert Califf Appointment

SWHR released a statement following the Senate’s confirmation of Dr. Robert Califf to serve as the Commissioner of Food and Drugs, Food and Drug Administration.

7.14.20 | Policy
SWHR Applauds House Appropriations Committee for Advancing HHS Funding Increases

In the midst of the COVID-19 pandemic, the work of U.S. public health agencies is more important than ever. SWHR commends the House Appropriations Committee on its approval of a FY21 appropriations bill increasing funding for NIH to $47 billion.

SWHR Stands With the Black Community Against Racial Injustice

The Society for Women’s Health Research stands with the Black community against racial injustice.

SWHR Launches Search for CEO in 2020

SWHR CEO Amy M. Miller announces that she is leaving in 2020 and SWHR begins search for new leader.

10.3.18 | Research and Clinical Trials
SWHR Applauds Report Addressing Research Gaps on Safe, Effective Therapies for Pregnant and Lactating Women

The Society for Women’s Health Research commends the Task Force on Research Specific to Pregnant Women and Lactating Women for its comprehensive, evidence-based report with pragmatic recommendations for addressing critical knowledge gaps on safe and effective medication for pregnant and lactating women.

SWHR Applauds Congress for Supporting Funding for NIH Office of Research on Women’s Health

SWHR commends Congress for recognizing the valuable role of NIH's Office of Research on Women's Health in the FY18 spending bill by calling for funding that reflects the office's important mission.

SWHR Lauds Passage and Signage of FDA Reauthorization Act of 2017 into Law

SWHR congratulates the Congress and the President for approving the Food and Drug Administration (FDA) Reauthorization Act of 2017. By providing significant funding and important improvements to FDA's medical products review and approval process, this law will enable timely access to safe and effective medical innovations to millions of patients who need them.

SWHR Calls on Congress to Make Significant Improvements to President’s 2018 Budget Proposal

SWHR is deeply concerned and discouraged to see that the Administration has deprioritized research and development in the 2018 budget through substantial decreases for critical federal agencies, expressed Dr. Amy M. Miller, SWHR president and CEO.

SWHR Supports Dr. Scott Gottlieb’s Confirmation to Lead FDA

Distinguished physician and health policy expert, Dr. Scott Gottlieb, has been confirmed by the Senate as the next Food and Drug Administration (FDA) Commissioner. President Donald Trump nominated him in March 2017.

Administrations May Change, But the Scientific Mission Should Not

The scientific community will gather this Earth Day, April 22, to take a public stand “to defend the vital role science plays in health, safety, economies, and governments,” at a March for Science event taking place in more than 500 cities across the world.